key: cord-0054191-mu5w62z3
authors: Verma, Subodh; Anker, Stefan D.; Butler, Javed; Bhatt, Deepak L.
title: Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective
date: 2020-12-22
journal: ESC Heart Fail
DOI: 10.1002/ehf2.13148
sha: 18242404b203c1bcf2e4c742b15c19cb5c6ce953
doc_id: 54191
cord_uid: mu5w62z3

nan

Worsening heart failure (WHF) requiring hospitalization represents a vulnerable period for patients with heart failure. 1,2 Such individuals, irrespective of the aetiology of heart failure, are at heightened risk of urgent heart failure visits, recurrent heart failure hospitalizations (HHF), and death. The early phase management of such patients is focused on the relief of congestion (with intravenous loop diuretics), stabilization of haemodynamics, and optimization of tissue perfusion. As clinical stabilization is achieved and successful weaning from intravenous to oral therapies has begun, this pre-discharge phase is characterized by optimization of evidence-based therapies, which in the case of heart failure with reduced ejection fraction (HFrEF) includes angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers/angiotensin receptor neprilysin inhibitors, β-blockers, and mineralocorticoid receptor antagonists. 3 These disease-modifying therapies, when instituted early, serve to markedly reduce morbidity and mortality following discharge. [4] [5] [6] [7] [8] [9] Sodium-glucose cotransporter 2 (SGLT2) inhibitors, originally described as therapies for hyperglycaemia, have now emerged as powerful tools to reduce heart failure outcomes in patients with HFrEF. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In two recently completed studies-DAPA-HF (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure) and EMPEROR-Reduced (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction)-dapagliflozin and empagliflozin, respectively, reduced the risk of cardiovascular death and HHF by 26% in patients with HFrEF. [20] [21] [22] Importantly, these benefits were observed consistently in those with and without type 2 diabetes, were in addition to excellent background heart failure therapies, and resulted in an improvement in patient reported quality of life indices. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] Because both trials recruited patients with chronic ambulatory HFrEF [and excluded patients with hospitalization due to decompensated heart failure less than 4 weeks prior to enrolment (DAPA-HF)], it can be argued that the question of in-hospital initiation of SGLT2 inhibitors during a WHF event has remained unanswered. In addition, whether SGLT2 inhibitors would be beneficial irrespective of ejection fraction was unclear.

To address these two questions, the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure) trial was conducted. 33 A total of 1222 patients with type 2 diabetes [with an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m 2 ] who had been recently hospitalized for WHF were studied. Patients had to be treated with intravenous diuretics during the index hospitalization, and prior to randomization had to be stable, off intravenous inotropes, off oxygen, and had to have transitioned to oral diuretics. In addition, participants had to have either a brain natriuretic peptide level of ≥150 pg/mL (≥450 pg/mL if atrial fibrillation was present) or an N-terminal pro-brain natriuretic peptide level of ≥600 pg/mL (≥1800 pg/mL if atrial fibrillation was present). Eligible patients were randomized to receive the SGLT2/SGLT1 inhibitor sotagliflozin (200 mg once daily with up-titration to 400 mg as tolerated) vs. placebo either before or within 3 days of discharge. Approximately 20% of patients randomized had an ejection fraction of ≥50%, and the median eGFR was~50 mL/min/1.73 m 2 . Half of the patients received their first dosing while still in the hospital and the other half within 3 days following discharge. The ultimate primary endpoint of SOLOST-WHF-which in order to preserve statistical power was changed because of the premature closure of the study due to loss of funding from the sponsor during the onset of the COVID-19 pandemic-was the composite of total HHF, urgent heart failure visits, or cardiovascular deaths. It was reduced by 33% in those receiving sotagliflozin vs. placebo [hazard ratio (HR) 0.67; 95% confidence interval (CI) (0.52, 0.85), P = 0.0009]. This translated into a number needed to treat of four patients for a year. The cumulative incidence curves for the primary outcome separated early and were significant by day 28 post-randomization. Efficacy was consistent across baseline ejection fraction (Figure 1 ), eGFR categories (above and below 60 mL/min/1.73 m 2 ), and in those who received initial therapy in-hospital vs. within 3 days of being discharged. The time to first event of either cardiovascular death or HHF was reduced by 29% [HR 0.71; 95% CI (0.56, 0.89); P = 0.003]. The hazard ratio for cardiovascular death was 0.84 [(95% CI 0.58, 1.22); P = 0.36].

The trial, which originally planned to enrol~4000 patients, had to be truncated, as noted above. Despite this challenge, the primary outcome (both the original and the revised) demonstrated a meaningful and statistically significant benefit of sotagliflozin, although the trial had limited power to detect differences in mortality. Treatment was also associated with a significant improvement in quality of life as reported by a 4.1-point increase in the Kansas City Cardiomyopathy Questionnaire-12 score in sotagliflozin-treated vs. placebotreated patients (P = 0.005). Beyond Week 4, the mean decrement in the eGFR was significantly lower in the sotagliflozin arm vs. placebo (P = 0.02). There were no major safety issues with sotagliflozin. Diarrhoea (6.9% vs. 4.1%) and severe hypoglycaemia (1.5% vs. 0.3%) were higher in the sotagliflozin-treated vs. placebo-treated patients.

There are several important take-aways from SOLOIST-WHF. First, in people with type 2 diabetes admitted with WHF requiring intravenous diuretics, SGLT2 inhibitors should be initiated as soon as the patient is clinically stable, preferably prior to discharge (or within days of discharge) during the phase of oral therapy optimization ( Figure 2 ). Prior studies of SGLT2 inhibitors, namely DAPA-HF and EMPEROR-Reduced, focused primarily on ambulatory patients with chronic HFrEF with and without diabetes. SOLOIST-WHF provides the first clinical trial evidence of efficacy of earlier initiation of SGLT2 inhibitors. The results of SOLOIST-WHF raise the possibility that this effect is present irrespective of baseline ejection fraction. By stratification factor at randomization, 256 patients had an EF classified as ≥50%, and the HR was 0.48 (95% CI 0.27, 0.86). Of the 1222 patients enrolled, 725 had an available baseline ejection fraction of <40% while 230 and 264 had ejection fractions of 40-49% and ≥50%, respectively. The HR for the primary outcome was apparently similarly reduced in all groups (0.69, 0.74, and 0.66, respectively). Because the subgroup of patients with ejection fraction above 50% was modest in size, further data of SGLT2 inhibitors in heart failure with preserved ejection fraction (HFpEF) are eagerly anticipated. 1 Classification based on available baseline LVEF value and does not correspond exactly with categories defined by the randomization stratification factor, which is shown in the top two rows of the figure. Randomization in the study was stratified by baseline LVEF (<50% and ≥50%), and the actual baseline value was also recorded in the study case report form. After unblinding of the database, it was noted that there were a small number of inconsistencies between the classification of patients based on the randomization stratification factor and available baseline LVEF value. Specifically, 3 patients randomized in the <50% stratum did not have an available LVEF value in the database, 9 patients with available LVEF value <50% were randomized in the ≥50% stratum, and 17 patients with available LVEF value ≥50% were randomized in the <50% stratum. 2 Post hoc. Adapted from Bhatt et al.

Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) trials further supports that there was a consistent benefit of sotagliflozin in HFpEF. The EMPEROR-Preserved (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction) 34 and DELIVER (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure; ClinicalTrials.gov Identifier: NCT03619213) trials that are ongoing will provide valuable information in those with HFpEF in the ambulatory setting. Ongoing studies in patients with acute heart failure that include people with and without diabetes will help answer this question further (DAPA ACT HF-TIMI 68, ClinicalTrials.gov Identifier: NCT04363697; EMPULSE, ClinicalTrials.gov Identifier: NCT04157751). While SOLOIST-WHF studied patients with type 2 diabetes, evidence from both DAPA-HF and EMPEROR-Reduced point toward an entirely consistent benefit of dapagliflozin and empagliflozin in those with and without type 2 diabetes. 27,31 Therefore, it would be reasonable to hypothesize that the benefits noted in SOLOIST-WHF would also extend to those without type 2 diabetes.

As expected, compared with DAPA-HF and EMPEROR-Reduced, patients enrolled in SOLOIST-WHF were at higher risk. Indeed, the placebo event rate for first cardiovascular death or HHF (per 100 patient years) was 48% in SOLOIST-WHF. In contrast, the placebo event rates in DAPA-HF and EM-PEROR-Reduced were 15.3% and 21%, respectively, in the entire cohort and 25.5% and 28.5% in those with diabetes. These data further emphasize how diabetes in the context of heart failure is associated with worse clinical outcomes. 35 Several mechanism(s) have been put forward to help explain the benefits of SGLT2 inhibition on heart failure. 14, [36] [37] [38] [39] The early separation of the curves (within days)-which is also seen for dapagliflozin in DAPA-HF 40 and for empagliflozin in EMPEROR-Reduced 30may point toward an important haemodynamic effect of SGLT2 inhibition in patients with heart failure. Indeed, recent human physiological studies in heart failure have indicated that SGLT2 inhibition promotes fractional sodium excretion within a few hours of treatment initiation-an effect that is exaggerated in the context of a loop diuretic. 41 In acute heart failure, the EMPA-RESPONSE-AHF (Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure) pilot study has shown an early effect on diuresis and reduction in whole body water content. 42 Other relevant mechanisms may include an increase in erythropoietin, 43 inhibition of the sympathetic nervous system, 36 improved kidney function, changes in substrate utilization, 38 direct myocardial effects, modulation of autophagy/mitophagy, and a stimulation of a fasting transcriptional paradigm. 44 SGLT2 inhibitors have also been shown to have favourable effects on left ventricular remodelling in people with and without diabetes and in those with systolic or diastolic dysfunction. [45] [46] [47] [48] While most of these mechanisms have been described with SGLT2 inhibitors per se, it is important to point out that sotagliflozin also Figure 2 The natural history of worsening heart failure and the stages of worsening heart failure that have been evaluated in clinical trial settings. DAPA-HF, Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure; EF, ejection fraction; EMPEROR-Reduced, EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction; GDMT, guideline-directed medical therapy; HFrEF, heart failure with a reduced ejection fraction; MRA, mineralocorticoid receptor antagonists; RASi, renin-angiotensin system inhibitors; WHF, worsening heart failure. Editorial inhibits SGLT1, which may have additional glycaemic and cardiovascular benefit. 49 Indeed, in the SCORED study 50 that was conducted in people with type 2 diabetes and chronic kidney disease, sotagliflozin was associated with significant haemoglobin A1C improvements at low eGFR levels (those at which conventional SGLT2 inhibitors do not demonstrate similar efficacy). SGLT1 inhibition may also produce distinct vascular effects, and that may explain the unique, early efficacy of sotagliflozin to reduce rates of ischaemic events (including stroke) in SCORED. The exact impact of the SGLT1 inhibition component of sotagliflozin in addition to its SGLT2 inhibitory effects may only be assessable in head-to-head studies.

In summary, SOLOIST-WHF argues strongly for more upstream use of SGLT2 and SGLT2/1 inhibitors in patients with WHF. A hospitalization for heart failure marks a vulnerable phase wherein failure to initiate guideline-directed medical therapy constitutes a major missed opportunity to reduce patient morbidity and mortality. In-hospital initiation of such therapy is an independent predictor of better medication adherence and outcomes. 51, 52 While recent data from the GWTG-HF (Get With the Guidelines-Heart Failure) registry suggest that a large proportion of patients with HFrEF would be candidates for SGLT2 inhibitor therapy, 51,52 the uptake of these life-saving therapies remains poor. As we celebrate the successes of this class of agents, 53 in addition to some of the emerging therapies for WHF (e.g. vericiguat, ferric carboxymaltose, and omecamtiv mecarbil), 54-56 clinicians and patients are now faced with more choices than they ever had. How to integrate, optimize, and overcome inertia remains the Achilles heel of contemporary heart failure management. 

Clinical course of patients with worsening heart failure with reduced ejection fraction

The vulnerable phase after hospitalization for heart failure

Acute heart failure: from pathophysiology to optimal treatment

Timely management of new-onset heart failure

Recognizing the significance of outpatient worsening heart failure

ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

Solution Set Oversight Committee

The DAPA-HF trial: a momentous victory in the war against heart failure

Can we declare a victory against cardio-renal disease in diabetes?

More CREDENCE for SGLT2 inhibition

Pump, pipes, and filter: do SGLT2 inhibitors cover it all?

The serendipitous story of SGLT2 inhibitors in heart failure

Prevention of heart failure with SGLT-2 inhibition: insights from CVD-REAL

Empagliflozin and heart failure

Two tales: one story. EMPEROR-Reduced and DAPA-HF. Circulation

A big win for diabetic kidney disease: CRE-DENCE

DAPA-CKD: the beginning of a new era in renal protection

fraction: the EMPEROR-reduced trial

Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status-results from the EMPEROR-Reduced trial

Empagliflozin and Health Related Quality of Life Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. The EMPEROR-Reduced Trial

SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure

Investigators. Evaluation of the effects of sodiumglucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved trial

Investigators RR. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry

Are the cardiorenal benefits of SGLT2 inhibitors due to inhibition of the sympathetic nervous system?

Empagliflozin's fuel hypothesis: not so soon

Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review

Effects of SGLT2 inhibitors on kidney and cardiovascular function

Timing of Onset of Clinical Benefit With Dapagliflozin in Patients With Heart Failure: An Analysis From the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF)

Renal effects of intensive volume removal in heart failure patients with preexisting worsening renal function

Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)

Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease

SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action

EMPA-TROPISM (ATRU-4) investigators. Randomized trial of empagliflozin in non-diabetic patients with heart failure and reduced ejection fraction

2 diabetes mellitus: the IDDIA trial

Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)

Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial

Sotagliflozin as a potential treatment for type 2 diabetes mellitus

Sotagliflozin in patients with diabetes and chronic kidney disease

Initiation, continuation, wwitching, and withdrawal of heart failure medical therapies during hospitalization

Outpatient adherence to betablocker therapy after acute myocardial infarction

AFFIRM-AHF heart failure: a multicentre, double-blind, randomised, controlled trial

Vericiguat in patients with heart failure and reduced ejection fraction

Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure

We would like to thank Hwee Teoh, PhD of HTaq Biomedical Editorial and Education Services Inc and M. Gail Rudakevich, MSc (BMC) of Synapse Visuals for their help in constructing the figures.